- Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. Van Cutsem E, Tabernero J, Lakomy R, et al. J Clin Oncol. 2012;30(28):3499-3506. Ver abstract.
- Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Tabernero J, Van Cutsem E, Lakomý R, et al. Eur J Cancer. 2014;50(2):320-321. Ver abstract.
- Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatinbased therapy. Ruff P, Ferry DR, Lakomy R, et al. Eur J Cancer. 2015;51(1):18-26. Ver abstract.
- Aflibercept plus FOLFIRI vs. placebo plus FOLFIRI in second-line metastatic colorectal cancer: a post hoc analysis of survival from the phase III VELOUR study subsequent to exclusion of patients who had recurrence during or within 6 months of completing adjuvant oxaliplatin-based therapy. Van Cutsem E, Joulain F, Hoff PM, et al. Target Oncol. 2016;11(3):383-400. Ver abstract.